Provided by Tiger Trade Technology Pte. Ltd.

CARSGEN-B

12.600
+0.1501.20%
Volume:2.95M
Turnover:36.66M
Market Cap:7.48B
PE:-71.08
High:12.750
Open:12.680
Low:12.050
Close:12.450
52wk High:28.600
52wk Low:10.870
Shares:594.00M
HK Float Shares:594.00M
Volume Ratio:1.43
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.177
ROE:-9.57%
ROA:-8.91%
PB:5.82
PE(LYR):-71.08
PS:46.84

Loading ...

CARsgen Therapeutics Reports Director Resignation and Audit Committee Shortfall Under HKEX Rule 3.21

Bulletin Express
·
Yesterday

Guo Huaqing Steps Down as Non-Executive Director of CARsgen-B (02171)

Stock News
·
Yesterday

CARSGEN-B (02171) Completes First Patient Infusion in China Phase I Registration Trial of CT1190B

Stock News
·
Sep 29

CARsgen Says First Patient Dosed in China Phase I Registrational Trial of Ct1190b CAR-T for R/R LBCL

Reuters
·
Sep 29

CARsgen-B Posts 1H 2026 Revenue Growth, Narrower Loss After Top-up Placement and Satri-cel Approval

Bulletin Express
·
Sep 15

CARSGEN-B (02171) Climbs Nearly 3% in Morning Trade as FNC Lymphodepletion Regimen Receives Official Patent in China

Stock News
·
Sep 14

HK Business Breakthrough Drives Nearly 5% Intraday Rally for CARSGEN-B

Deep News
·
Sep 11

CARsgen Therapeutics (SEHK:2171) Stock Carries Premium Valuation Despite Ongoing Losses

Simply Wall St.
·
Aug 19

CARSGEN-B Surges Nearly 5% Post-Earnings as Mid-Year Revenue Climbs 21.5% to RMB 61.9 Million

Deep News
·
Aug 19

Press Release: CARsgen Therapeutics Announces 2026 Interim Results

Dow Jones
·
Aug 19

CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich

Simply Wall St.
·
Aug 19

CARsgen Therapeutics posts narrower interim loss; revenue up 21.5% on BCMA CAR-T sales, cash boosted by HK$462 million placing

Bulletin Express
·
Aug 18

CARsgen-B Posts Interim Results with 11.52% Narrower Loss Attributable to Owners

Stock News
·
Aug 18

CARsgen FY26 H1 Net Loss Narrows to RMB 70.84 Million; Revenue Rises 21.49% to RMB 61.92 Million

Reuters
·
Aug 18

CARsgen Therapeutics Wins China IND Clearance for Lymphoma Cell Therapy

MT Newswires Live
·
Aug 07

CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure

Stock News
·
Aug 07

CARSGEN-B Receives IND Clearance from Chinese Drug Regulator for Novel Cell Therapy Targeting Lymphoma

Stock News
·
Aug 07

CARsgen Says NMPA Clears IND for Ct1190b in Relapsed/refractory Large B-Cell Lymphoma

Reuters
·
Aug 07

CARsgen Therapeutics - Ct1190b Receives Ind Clearance from Nmpa for Relapsed/Refractory Large B-Cell Lymphoma

THOMSON REUTERS
·
Aug 07

CARsgen Schedules 18 Aug 2026 Board Meeting to Approve 1H 2026 Interim Results

Bulletin Express
·
Aug 06